Literature DB >> 20807771

Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay.

Tanja Ouimet1, Sou-Vinh Orng, Hervé Poras, Khatuna Gagnidze, Lakshmi A Devi, Marie-Claude Fournié-Zaluski, Bernard P Roques.   

Abstract

Endothelin-converting enzyme-2 (ECE-2) is a membrane-bound zinc-dependent metalloprotease that shares a high degree of sequence homology with ECE-1, but displays an acidic pH optimum characteristic of maturing enzymes acting late in the secretory pathway. Although ECE-2, like ECE-1, can cleave the big endothelin intermediate to produce the vasoconstrictive endothelin peptide, its true physiological function remains to be elucidated, a task that is hampered by the lack of specific tools to study and discriminate ECE-2 from ECE-1, i.e. specific substrates and/or specific inhibitors. To fill this gap, we searched for novel ECE-specific peptide substrates. To this end, peptides derived from the big endothelin intermediate were tested using ECE-1 and ECE-2, leading to the identification of an ECE-1-specific substrate. Moreover, screening of our proprietary fluorigenic peptide Fluofast® libraries using ECE-1 and ECE-2 allowed the identification of Ac-SKG-Pya-F-W-Nop-GGK-NH(2) (PL405), as a specific and high affinity ECE-2 substrate. Indeed, ECE-2 cleaved PL405 at the Pya-F amide bond with a specificity constant (k(cat)/K(m)) of 8.1 ± 0.9 × 10(3) M(-1) s(-1). Using this novel substrate, we also characterized the first potent (K(i) = 7.7 ± 0.3 nM) and relatively selective ECE-2 inhibitor and developed a quantitative fluorigenic ECE-2 assay. The assay was used to study the ex vivo ECE-2 activity in wild type and ECE-2 knock-out tissues and was found to truly reflect ECE-2 expression patterns. The PL405 assay is thus the first tool to study ECE-2 inhibition using high throughput screening or for ex vivo ECE-2 quantification.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807771      PMCID: PMC2966053          DOI: 10.1074/jbc.M110.120576

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme.

Authors:  Elizabeth A Eckman; Mona Watson; Laura Marlow; Kumar Sambamurti; Christopher B Eckman
Journal:  J Biol Chem       Date:  2002-12-02       Impact factor: 5.157

2.  Molecular cloning and primary structure of Kell blood group protein.

Authors:  S Lee; E D Zambas; W L Marsh; C M Redman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

3.  Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin.

Authors:  S L Roderick; M C Fournie-Zaluski; B P Roques; B W Matthews
Journal:  Biochemistry       Date:  1989-02-21       Impact factor: 3.162

Review 4.  Zinc metallopeptidases: active site structure and design of selective and mixed inhibitors: new approaches in the search for analgesics and anti-hypertensives.

Authors:  B P Roques
Journal:  Biochem Soc Trans       Date:  1993-08       Impact factor: 5.407

Review 5.  Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.

Authors:  B P Roques; F Noble; V Daugé; M C Fournié-Zaluski; A Beaumont
Journal:  Pharmacol Rev       Date:  1993-03       Impact factor: 25.468

6.  cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone.

Authors:  L Du; M Desbarats; J Viel; F H Glorieux; C Cawthorn; B Ecarot
Journal:  Genomics       Date:  1996-08-15       Impact factor: 5.736

7.  Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.

Authors:  M C Fournié-Zaluski; W Gonzalez; S Turcaud; I Pham; B P Roques; J B Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

8.  Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. OFF.

Authors:  K Ohnaka; R Takayanagi; M Nishikawa; M Haji; H Nawata
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

9.  Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum.

Authors:  N Emoto; M Yanagisawa
Journal:  J Biol Chem       Date:  1995-06-23       Impact factor: 5.157

10.  ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1.

Authors:  D Xu; N Emoto; A Giaid; C Slaughter; S Kaw; D deWit; M Yanagisawa
Journal:  Cell       Date:  1994-08-12       Impact factor: 41.582

View more
  4 in total

1.  Opioid receptor function is regulated by post-endocytic peptide processing.

Authors:  Achla Gupta; Ivone Gomes; Jonathan Wardman; Lakshmi A Devi
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

2.  Endothelin-converting enzyme 2 differentially regulates opioid receptor activity.

Authors:  A Gupta; W Fujita; I Gomes; E Bobeck; L A Devi
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 3.  Neprilysin Inhibitors and Bradykinin.

Authors:  Duncan J Campbell
Journal:  Front Med (Lausanne)       Date:  2018-09-19

4.  Identification of Hypoxia-Specific Biomarkers in Salmonids Using RNA-Sequencing and Validation Using High-Throughput qPCR.

Authors:  Arash Akbarzadeh; Aimee Lee S Houde; Ben J G Sutherland; Oliver P Günther; Kristina M Miller
Journal:  G3 (Bethesda)       Date:  2020-09-02       Impact factor: 3.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.